ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 278

Corticosteroid Use, Biologic Therapy Switching, Smoking and Renal Failure Are Associated with Serious Infections in Rheumatoid Arthritis Patients Treated with Biologics: Data from Two Latin-American Registries

Maria de la Vega1, Gustavo Casado2, Gustavo Citera2, Ieda Maria Magalhães Laurindo3, Georges Christopoulos3, Miguel Angel Descalzo4 and Roberto Ranza5, 1on behalf of BiobadaSar study group, Sociedad Argentina de Reumatologia, Buenos aires, Argentina, 2on behalf of BiobadaSar study group, Sociedad Argentina de Reumatologia, Buenos Aires, Argentina, 3on behalf of the BiobadaBrasil study group, Sociedade Brasileira de Reumatologia, São Paulo, Brazil, 4Unidad de Investigación Fundación Piel Sana Academia Española de Dermatología y Venerología, Madrid, Spain, 5on behalf of the BiobadaBrasil study group, Sociedade Brasileira de Reumatologia, Uberlandia, Brazil

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Safety issues and biologic drugs

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Infection-related Rheumatic Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Infections are the most frequent and concerning serious adverse events related to rheumatoid arthritis (RA) treatment with biologic drugs (bDMARDs). Their safety profile might have substantial regional differences. In January 2009 started BiobadaAmerica, a common platform registry project open to all Latin American countries, focused on safety monitoring of bDMARDs. Purpose of this study is to present data on factors associated with serious infections (SI) in patients with RA exposed to bDMARDs in two Latin-American not mandatory registries.

Methods: Data from Argentinian Registry (BiobadaSar) and Brasilian Registry (BiobadaBrazil), both initiated in 2010, were downloaded on December 31, 2016, merged and analyzed. The same constant monitoring process guaranteed data quality. Patients with rheumatic diseases were included prospectively when started the first bDMARD. Time of exposure was set from start of the drug to the date of last administration or censorship. SI incidence rate was calculated per 1000 patient/years with 95%CI

Results: Data from 2591 RA patients were analyzed, for a total of 9300 p/y. Treatments were 3784, 64% aTNF (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab), 36% non-aTNF (Abatacept, Rituximab, Tocilizumab) including Tofacitinib. Females 85%, at baseline mean age 53 (SD 12.8)yrs , mean disease duration 10(8.5)yrs, mean follow-up 2.7 (2) yrs. The overall incidence rate of SI was 30.54 (CI 27.18-34.30), Comparing patients with (191) and without (2400) SI, age, sex, disease duration, use of concomitants DMARD, presence of diabetes mellitus or pulmonary chronic disease and a positive history of previous câncer did not differ statistically. Exposition to more than one bDMARD (p<0.01), corticosteroid use (p=<0.01), smoking (p=0.01) and presence of renal failure (p=0.03) were statistically associated with SI. Unexpectedly, basal DAS28 was higher in patients without SI (p=0.03).

Conclusion: Corticosteroid use, exposition to more than one biologic, smoking and renal failure are associated with serious infections in RA patients on bDMARDs.


Disclosure: M. de la Vega, None; G. Casado, None; G. Citera, AbbVie, Bristol-Myers Squibb, Janssen, Novartis, Pfizer Inc, 5,Novartis, Pfizer Inc, 2,AbbVie, Bristol-Myers Squibb, Janssen, Novartis, Pfizer Inc, 5; I. M. M. Laurindo, None; G. Christopoulos, None; M. A. Descalzo, None; R. Ranza, None.

To cite this abstract in AMA style:

de la Vega M, Casado G, Citera G, Laurindo IMM, Christopoulos G, Descalzo MA, Ranza R. Corticosteroid Use, Biologic Therapy Switching, Smoking and Renal Failure Are Associated with Serious Infections in Rheumatoid Arthritis Patients Treated with Biologics: Data from Two Latin-American Registries [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/corticosteroid-use-biologic-therapy-switching-smoking-and-renal-failure-are-associated-with-serious-infections-in-rheumatoid-arthritis-patients-treated-with-biologics-data-from-two-latin-american-r/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/corticosteroid-use-biologic-therapy-switching-smoking-and-renal-failure-are-associated-with-serious-infections-in-rheumatoid-arthritis-patients-treated-with-biologics-data-from-two-latin-american-r/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology